LifeSemantics Corp. (347700) - Total Liabilities
Based on the latest financial reports, LifeSemantics Corp. (347700) has total liabilities worth ₩408.85 Billion KRW (≈ $277.07 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of LifeSemantics Corp. to evaluate the company's liquid asset resilience ratio.
LifeSemantics Corp. - Total Liabilities Trend (2017–2025)
This chart illustrates how LifeSemantics Corp.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see LifeSemantics Corp. balance sheet assets.
LifeSemantics Corp. Competitors by Total Liabilities
The table below lists competitors of LifeSemantics Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangmen iDear-Hanyu Electrical Joint-Stock Co Ltd
SHE:300403
|
China | CN¥370.65 Million |
|
Contrel Technology Co Ltd
TWO:8064
|
Taiwan | NT$2.14 Billion |
|
Pan-International Industrial Corp
TW:2328
|
Taiwan | NT$6.81 Billion |
|
Samsung Fire And Marine Ins Pref
KO:000815
|
Korea | ₩75.16 Trillion |
|
Sinopec Oilfield Equipment Corp
SHE:000852
|
China | CN¥7.19 Billion |
|
D-MARKET Electronic Services & Trading ADR
NASDAQ:HEPS
|
USA | $31.93 Billion |
|
DNA Link Inc
KQ:127120
|
Korea | ₩53.95 Billion |
|
Prima Andalan Mandiri Tbk PT
JK:MCOL
|
Indonesia | Rp158.96 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down LifeSemantics Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See LifeSemantics Corp. balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.99 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.80 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LifeSemantics Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LifeSemantics Corp. (2017–2025)
The table below shows the annual total liabilities of LifeSemantics Corp. from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩31.72 Billion ≈ $21.50 Million |
+136.91% |
| 2024-12-31 | ₩13.39 Billion ≈ $9.07 Million |
+33.13% |
| 2023-12-31 | ₩10.06 Billion ≈ $6.82 Million |
-39.28% |
| 2022-12-31 | ₩16.56 Billion ≈ $11.22 Million |
-18.12% |
| 2021-12-31 | ₩20.23 Billion ≈ $13.71 Million |
+175.06% |
| 2020-12-31 | ₩7.35 Billion ≈ $4.98 Million |
-24.89% |
| 2019-12-31 | ₩9.79 Billion ≈ $6.63 Million |
+28.85% |
| 2018-12-31 | ₩7.60 Billion ≈ $5.15 Million |
+61.89% |
| 2017-12-31 | ₩4.69 Billion ≈ $3.18 Million |
-- |
About LifeSemantics Corp.
Sphere Corp. provides digital healthcare technology, and life care products and services. It develops LifeRecord, a commercial personal health record platform that manages health-related data, including medical records, genome data, and personally generated health data. The company also offers digital healthcare services for consumers, such as non-face-to-face treatment, medication management, an… Read more